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Objective: Circulating 8-iso-prostaglandin F2 (8-iso-PGF2) has been proposed as new indicator of oxidative stress,
which is involved in the pathophysiologic changes of atherosclerosis. We proposed to test the hypothesis that 8-iso-PGF2
is an independent predictor of symptomatic peripheral arterial disease (PAD).
Methods: A case-control study in 100 patients with symptomatic PAD and 100 control subjects matched for age, sex, and
diabetes mellitus was conducted. Smokers and subjects using lipid-lowering drugs were excluded. Serum total 8-iso-
PGF2 was quantified with an enzyme immunoassay.
Results: Median 8-iso-PGF2 was higher in patients with PAD than in control subjects (63 vs 42 pg/mL; P  .001).
Logistic regression with hypertension, body mass index, and creatinine, low-density lipoprotein (LDL) cholesterol,
triglyceride, high-sensitivity C-reactive protein (hs-CRP), 8-iso-PGF2, and total homocysteine concentrations as
independent variables and case-control status as dependent variable revealed significant odds ratios (OR) for hyperten-
sion (OR, 3.74; 95% confidence interval [CI], 1.85-7.53), low-density lipoprotein cholesterol (OR, 1.16, for an
increment of 10 mg/dL; 95% CI, 1.07-1.27), high-sensitivity C-reactive protein (OR, 1.02, for an increment of 1 mg/L;
95% CI, 1.00-1.03), and 8-iso-PGF2 (OR, 1.11, for an increment of 10 pg/mL; 95% CI, 1.03-1.20).
Conclusions: Serum total 8-iso-PGF2 was an independent predictor of PAD in the population studied. This finding
supports the hypothesis that 8-iso-PGF2 is a risk marker for PAD. Our results indicate increased systemic oxidative stress
in patients with PAD. (J Vasc Surg 2004;40:768-73.)Peripheral arterial disease (PAD) is an important man-
ifestation of systemic atherosclerosis, and is associated with
elevated risk for cardiovascular and cerebrovascular events
including death, myocardial infarction, and stroke.1 Diabe-
tes mellitus and smoking are the strongest risk factors for
PAD.1,2 Other well-known risk factors are advanced age,
male sex, arterial hypertension, and hyperlipidemia.1,2
Emerging risk factors for PAD include elevated levels of
high-sensitivity C-reactive protein (hs-CRP) and total ho-
mocysteine (tHcy).2,3 Although oxidative stress is involved
in the pathophysiologic changes of atherosclerosis and car-
diovascular disease,4 only scarce data are available as to the
extent that oxidative damage is also related to PAD.
In the atherosclerotic process lipids are the first line of
radical attack, and the isoprostanes are stable end products
of lipid peroxidation.5 Isoprostanes, structural isomers of
the prostaglandins, are a family of compounds produced
from polyunsaturated fatty acids via a free radical–catalyzed
mechanism. The isoprostane family includes F2-isopros-
tane, D2-isoprostane, E2- isoprostane, and isothrombox-
ane A2, F2-isoprostanes are the most abundant.
5 Isopros-
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ester forms, whereas only hydrolized isoprostanes are ex-
creted into urine.6,7 F2-isoprostanes, among them 8-iso-
prostaglandin F2 (8-iso-PGF2), have been proposed as
new indicators of oxidative stress,8-10 and it has been sug-
gested that their measurement is the most accurate method
for quantifying oxidant stress in human beings.9
Previous research focused on the role of circulating and
urinary 8-iso-PGF2 in coronary artery disease (CAD), and
demonstrated that 8-iso-PGF2 levels are elevated in pa-
tients with CAD and myocardial ischemia.11-13 Inasmuch
as there are currently no published data on PAD and
8-iso-PGF2, we proposed to test the hypothesis that cir-
culating 8-iso-PGF2 is an independent predictor of symp-
tomatic chronic limb ischemia, that is, PAD. The relation of
8-iso-PGF2 with atherosclerotic disease may be affected
by a number of confounding factors, such as age, diabetes
mellitus, and cigarette smoking.10 Because medication
with 3-hydroxy-3-methylglutaryl coenzyme A inhibitors is
also thought to affect 8-iso-PGF2 levels,
14 statistical mod-
els testing the relation of underlying metabolic effects with
PAD become increasingly complex in a study population
including these conditions. Therefore we intended to ad-
dress the association of 8-iso-PGF2 in a population devoid
of the mentioned confounding factors by conducting a
case-control study, with the study subjects matched for age,
sex, and diabetes mellitus, and excluding smokers as well as
subjects using any lipid-lowering drugs.
METHODS
Patients and study protocol. The present study, per-
formed at the Division of Vascular Surgery, Department of
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case-control study of patients with symptomatic chronic
limb ischemia, that is, PAD, and control subjects without
clinically relevant atherosclerotic disease. All study subjects
underwent evaluation for the presence of risk factors for
atherosclerosis and comorbid conditions, as recommend-
ed.15 PAD was defined as atherosclerotic occlusive disease
of the lower extremities associated with typical symptoms,
such as claudication or leg pain upon exertion, rest pain, or
minor or major tissue loss, and was verified by interview,
physical examination, noninvasive techniques, and an-
giograpy. CAD was defined as remote myocardial infarc-
tion by history, occult myocardial infarction by electrocar-
diography, previous coronary bypass surgery or
percutaneous transluminal coronary angioplasty, and stable
or unstable angina (cardiac troponin positive) and acute
coronary syndrome (cardiac troponin negative). Cerebro-
vascular disease (CVD) was defined as transient or tempo-
rary stroke, completed stroke with permanent neurologic
deficit, or acute stroke. In patients and control subjects
Doppler segmental blood pressure of the lower limbs,
including continuous-wave spectral analysis and resting
ankle-brachial index (ABI) measurements, as well as color
duplex ultrasound scanning of the carotid bifurcation and
the internal carotid artery were carried out as de-
Table I. Clinical and biochemical data of patients with PA
PAD grou
Male/female (no.) 47/53
Age (y) 76 (70-80
Body mass index (kg/m2) 26 (24-29
Arterial hypertension (no.) 75
Diabetes mellitus (no.) 27
Coronary artery disease (no.) 33
Cerebrovascular disease (no.) 26
Carotid stenosis 50% (no.) 32
PAD-relevant data
Previous PTA/stenting (no.) 21
Previous vascular surgery (no.) 20
Previous amputation (no.) 2
ABI (mm Hg/mm Hg) 0.82 (0.6
Biochemical markers
Creatinine (mg/dL) 1.0 (0.9-1
Total-cholesterol (mg/dL) 224 (192
LDL-cholesterol (mg/dL) 156 (118
HDL-cholesterol (mg/dL) 51 (41-60
Triglycerides (mg/dL) 127 (101
Fasting glucose (mg/dL)¶ 97 (88-10
HbA1c (%)
¶ 5.9 (5.7-6
hs-CRP (mg/L) 4.1 (2.0-9
8-iso-PGF2 (pg/mL) 63 (39-85
Total homocysteine (mol/L) 17.0 (14.
Folate (ng/mL) 7.4 (5.0-9
Vitamin B12 (pg/mL) 364 (241
PAD, Peripheral arterial disease; PTA, percutaneous transluminal angiop
high-density lipoprotein; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity
Age, body mass index, ABI, and biochemical markers are presented as med
*Nonparametric Mann-Whitney U test or Fisher exact test, as appropriate.
†Matched variables.
‡P not significant after Bonferroni correction for multiple comparisons.
¶Subjects with diabetes mellitus were excluded.scribed.16,17 Patients and control subjects had been non-
smokers for at least 10 years, and use of any lipid-lowering
drugs or vitamin supplements were exclusion criteria for the
PAD and control groups. The study protocol was approved
by the local ethics committee in accordance to the Helsinki
Declaration, and all study participants gave informed con-
sent.
A total of 100 patients, admitted for inpatient treat-
ment of symptomatic PAD (claudication or leg pain on
exertion, rest pain, minor or major tissue loss), were re-
cruited and examined according to standard procedures. In
addition to Doppler segmental blood pressure of the lower
limbs and resting ABI measurements, aortofemoral angiog-
raphy was performed in all patients to confirm the presence
of PAD and to determine the location and extent of wall
changes. The control group consisted of 100 subjects
matched to the patients with PAD in a 1:1 design by sex,
age (2 years), and diabetes mellitus. All control subjects
were patients in our hospital, and fulfilled the following
criteria: no clinical indication of PAD by history and phys-
ical examination; systolic brachial blood pressure equal to
or less than the blood pressure in each of the right and left
anterior tibial and posterior tibial arteries, respectively (ie,
ABI 1.0); no pathologic pattern of pulse waves in lower
limbs by continuous-wave spectral analysis; no CAD; no
d control subjects
 100) Control group (n  100) P*
47/53 1.000†
76 (69-80) .826†
26 (24-28) .795
52 .001
27 1.000†
0 —
0 —
0 —
0 —
0 —
0 —
0) 1.23 (1.13-1.32) —
0.9 (0.8-1.1) .056
211 (186-246) .037‡
139 (107-155) .001
54 (43-69) .155
114 (81-154) .034‡
95 (88-104) .379
5.7 (5.4-6.1) .010‡
1.6 (0.8-4.2) .001
42 (24-70) .001
4) 16.2 (13.4-19.7) .167
7.0 (5.7-9.1) .717
309 (234-441) .218
ABI, resting ankle-brachial index; LDL, low-density lipoprotein; HDL,
8-iso-PGF2; 8-iso-prostaglandin F2.
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nal carotid arteries; and no stenosis of the internal carotid
artery 50% or greater on color duplex ultrasound scans. All
control subjects were generally in good health, and were
admitted for treatment of minor health problems, such as
cataract surgery, vertebragene pain, or nonvascular surgery
(eg, herniotomia, varicose vein extirpation).
Biochemical analysis. Blood was collected at veni-
puncture in Vacuette polyethylene terephthalate glycol clot
activator tubes (Greiner Bio-One) after the patient had
fasted overnight. Creatinine, fasting glucose, glycohemo-
globin A1c (HbA1c), total cholesterol, and triglyceride con-
centrations were analyzed with standard assays on a CO-
BAS Integra analyzer (Roche Diagnostics). For
determination of high-density lipoprotein cholesterol and
LDL cholesterol quantitative electrophoresis with enzy-
matic staining (Helena BioSciences) was used. tHcy, folate,
and vitamin B12 assays were performed on an AxSYM
analyzer (Abbott Diagnostics). Concentration of CRP was
measured with a high-sensitivity assay (N High Sensitivity
CRP) on a BN ProSpec analyzer (Dade Behring) with
polystyrene particles coated with monoclonal mouse anti-
bodies to CRP. Serum samples for total 8-iso-PGF2 (ie,
free and esterified 8-iso-PGF2) determination were imme-
diately frozen and stored at 80°C until assessment. After
hydrolyzation of isoprostanes by incubation with potas-
sium hydroxide at 40°C for 1 hour, the samples were
brought to pH 7.0 to 7.4 with KH2PO4 and purified with
a commercially available 8-isoprostane purification kit (im-
munoaffinity method; Cayman Chemicals). 8-iso-PGF2
was then quantified with a competition enzyme immuno-
assay (Cayman Chemicals). Samples from corresponding
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Fig 1. Box-and-whisker plots of 8-iso-prostaglandin F2 (PGF2)
for patients with peripheral arterial disease (PAD; n  100) and
control subjects (n  100). In box-and-whisker plots, central box
represents values from lower to upper quartile, middle line repre-
sents median; whiskers extend from minimum to maximum value,
excluding outside values (1.5 box lengths from box) and far out
values (3 box lengths from box), which are displayed as separate
points.patients with PAD and control subjects were assayed on the
same microwell plates. The whole procedure of 8-iso-
PGF2 determination was performed according to the
manufacturers’ recommendations.
Statistical analysis. Statistical analysis was performed
with SPSS version 10.0 software. Dichotomous variables
are given as prevalence in number, continuous data are
expressed as median (25th—75th percentiles). Univariate
comparisons of risk factors and other dichotomous vari-
ables between study groups were calculated with the Fisher
exact test, and continuous variables were evaluated with the
nonparametric Mann-Whitney U test (respective P values
were not adjusted for multiple comparisons, and are there-
fore only descriptive). To determine multivariate odds ra-
tios (OR) for PAD, logistic regression without variable
selection was performed. Dichotomous risk factors were
coded with an indicator variable of 1 for having the condi-
tion and 0 for its absence. Spearman’s coefficient of rank
correlation () was used for assessment of the relationship
of continuous data in the study population. Probabilities
are 2-tailed, and P  .05 is regarded as statistically signifi-
cant.
RESULTS
Patients with PAD were admitted because of mild to
severe claudication or leg pain on exertion (n 76), ischemic
rest pain (n 1), and minor or major tissue loss (n 23). Of
the 100 patients with PAD 33 had concomitant CAD and 26
had concomitant CVD. Furthermore, 25 patients with PAD
exhibited internal carotid stenosis 50% or greater. Another 7
patients with PAD were classified as having stenosis 50% or
greater as well, because they had undergone previous carotid
surgery to treat stenosis. At enrolment, 21 patients with PAD
had undergone remote percutaneous transluminal angio-
plasty with or without stenting, 20 patients with PAD had
undergone vascular surgery, and 2 patients with PAD had
undergone minor amputations. Per definition, none of the
100 control subjects matched to the patients with PAD for
sex, age (2 years), and diabetes mellitus had either CAD or
CVD, or internal carotid stenosis 50% or greater. However,
many control subjects (n 91) exhibited carotid plaques as a
sign of mild but not clinically relevant atherosclerosis. At
enrolment, 47 patients with PAD and 16 control subjects
received low-dose aspirin daily, and none of the 200 study
participants received cyclooxygenase 1 or 2 inhibitors. After
enrolment in the present study, 20 patients with PAD under-
went vascular surgery, including open revascularization pro-
cedures or bypass graft placement; in 28 patients endovascular
techniques, such as percutaneous transluminal angioplasty
with or without stenting, were performed; 3 patients under-
went lumbar sympathectomy; major amputation was per-
formed in 1 patient, and minor amputation in 2 patients; and
46 patients with PAD received conservative treatment.
The clinical and biochemical characteristics of all study
participants are described in Table I. Arterial hypertension
was significantly more prevalent in the PAD group (n 75)
compared with the control group (n  52; P  .001). In
addition, median values of the following biochemical mark-
JOURNAL OF VASCULAR SURGERY
Volume 40, Number 4 Mueller et al 771ers were significantly higher in patients with PAD than in
control subjects: total cholesterol (224 vs 211 mg/dL; P
.037), LDL cholesterol (156 vs 139 mg/dL; P  .001),
triglycerides (127 vs 114 mg/dL; P .034), HbA1c (5.9%
vs 5.7%; P  .010), hs-CRP (4.1 vs 1.6 mg/L; P  .001),
and total 8-iso-PGF2 (63 vs 42 pg/mL; P  .001). The
box-and-whisker plots in Fig 1 show the distribution of
8-iso-PGF2 values in the 2 study groups. Investigating
8-iso-PGF2 in the patients with PAD (n 100), we found
no difference of median 8-iso-PGF2 values between those
with claudication (n  76) and those with critical limb
ischemia (ischemic rest pain, minor or major tissue loss; n
24; 66 vs 58 pg/mL; P  .283).
Multivariate ORs for symptomatic PAD in the popula-
tion studied, calculated without variable selection tech-
nique, are shown in Tables II and III. Inasmuch as patient
and control groups were matched for age, sex, and diabetes
mellitus, these variables were not included in the regression
analysis. In the multivariate model, total 8-iso-PGF2 was
an independent and significant predictor (P  .006) of
case-control status, with an OR of 1.11 (95% confidence
interval [CI], 1.03-1.20), for an increment of 10 pg/mL.
In this analysis arterial hypertension (OR, 3.74; 95% CI,
Table II. Results of logistic regression analyses of PAD ris
Statistical model with an incremental approach for continu
Change in risk factor
Multiv
ratio f
Body mass index (	5 kg/m2) 0
Arterial hypertension (vs not) 3
Creatinine (	0.1 mg/dL) 0
LDL-cholesterol (	10 mg/dL) 1
Triglycerides (	10 mg/dL) 1
hs-CRP (	1 mg/L) 1
8-iso-PGF2 (	10 pg/mL) 1
Total homocysteine (	5 mol/L) 1
PAD, Peripheral arterial disease; LDL, low-density lipoprotein; hs-CRP, hi
interval.
*Multivariate odds ratios were calculated with logistic regression analysis wi
the model).
Table III. Results of logistic regression analyses of PAD r
Statistical model with continuous variables dichotomized a
200)
Change in risk factor
Body mass index ( median value of 26 kg/m2)
Arterial hypertension (vs not)
Creatinine ( median value of 1.0 mg/dL)
LDL cholesterol ( median value of 144 mg/dL)
Triglycerides ( median value of 121 mg/dL)
hs-CRP ( median value of 2.9 mg/L)
8-iso-PGF2 ( median value of 51 pg/mL)
Total homocysteine ( median value of 16.6 mol/L)
PAD, Peripheral arterial disease; LDL, low-density lipoprotein; hs-CRP,
confidence interval.
*Multivariate odds ratios were calculated with logistic regression analysis wi
the model).1.85-7.53; P  .001), LDL cholesterol (OR, 1.16, for an
increment of 10 mg/dL; 95% CI, 1.07-1.27; P  .001),
and hs-CRP (OR, 1.02, for an increment of 1 mg/L; 95%
CI, 1.00-1.03; P  .035) were also independently related
to symptomatic PAD. All other variables failed to reach
statistical significance; body mass index, and creatinine,
triglyceride, and tHcy concentrations revealed no signifi-
cant ORs. Stepwise logistic regression models revealed the
same predictors, with similar ORs compared with the mod-
els without variable selection technique (data not shown).
To test the relation of the 3 main biochemical markers
(LDL cholesterol, hs-CRP, 8-iso-PGF2) with each other
we used rank correlation analysis. As a result, there was no
significant correlation for either 8-iso-PGF2 and hs-CRP
(rank correlation coefficient [rs]0.079; 95% CI,0.216-
0.060; P  .264), nor for 8-iso-PGF2 and LDL choles-
terol (rs, 0.042; 95% CI, 0.097-0.180; P  .555). Even
when using dichotomized variables according to the
thresholds specified in Table III (median 8-iso-PGF2, and
hs-CRP and LDL cholesterol levels for the entire study
population), there was no significant association between
these analytes, indicating that there was no substantial
degree of overlap between the elevated levels of the 3
tors (100 patients with PAD vs 100 control subjects):
ariables
odds
D* 95% CI P
0.53-1.17 .244
1.85-7.53 .001
0.93-1.06 .822
1.07-1.27 .001
0.96-1.06 .779
1.00-1.03 .035
1.03-1.20 .006
0.88-1.47 .328
sitivity C-reactive protein; 8-iso-PGF2; prostaglandin F2; CI, confidence
variable selection technique (all variables were included simultaneously into
ctors (100 patients with PAD vs 100 control subjects).
ding to median values of entire study population (n 
Multivariate odds
ratio for PAD* 95% CI P
0.99 0.51-1.93 .977
2.02 1.42-2.88 .001
1.04 0.53-2.06 .901
2.77 1.42-5.41 .003
1.06 0.55-2.07 .856
3.34 1.70-6.57 .001
3.83 1.92-7.65 .001
1.30 0.67-2.55 .438
senstitivity C-reactive protein; 8-iso-PGF2; 8-iso-prostaglandin F2; CI,
variable selection technique (all variables were included simultaneously intok fac
ous v
ariate
or PA
.79
.74
.99
.16
.01
.02
.11
.14
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information is provided in Fig 2, A and B).
DISCUSSION
To our knowledge, this is the first report on 8-iso-
PGF2 as a potential risk factor for PAD. The main finding
of the present study was an approximately 1.5-fold higher
median circulating total 8-iso-PGF2 level in patients with
symptomatic PAD compared with control subjects. Given
that 8-iso-PGF2 has been proposed as a reliable marker of
oxidative damage,8-10 our results indicate increased sys-
temic oxidative stress in patients with PAD. Furthermore,
total 8-iso-PGF2 was a predictor of PAD in the multivar-
iate logistic regression model, independent of other covari-
ates associated with 8-iso-PGF2,
10 such as age, sex, and
diabetes mellitus (matched variables), as well as arterial
hypertension, body mass index, hypercholesterolemia
(controlled variables). In addition, the previously reported
effect of cigarette smoking18 and intake of 3-hydroxy-3-
methylglutaryl coenzyme A inhibitors14 on 8-iso-PGF2
was not evident in our population, because both conditions
were exclusion criteria of the present study. As demon-
strated with logistic regression analysis (Table III), the
association of 8-iso-PGF2 with PAD was similar to the
effect of other risk factors for PAD, that is, arterial hyper-
tension, elevated LDL cholesterol, and hs-CRP. Thus our
results are in line with recent findings that demonstrate that
circulating and urinary 8-iso-PGF2 may be independent
risk markers for CAD.11,13
As shown in Fig 2, A, no statistically significant corre-
lation between 8-iso-PGF2 and hs-CRP was found in our
study population. A previous study13 showed a weak cor-
relation between these 2 analytes, possibly resulting in part
Fig 2. Scatterplots for 8-iso-prostaglandin 2 (PGF2; h
(hs-CRP) and low-density lipoprotein (LDL) cholesterol
Distribution in entire study population (	, 100 patien
subjects) is demonstrated by number of subjects in each
for 8-iso-PGF2 vs hs-CRP: 0.079 (95% confidence
dichotomized variables according to median 8-iso-PGF2
correlation for 8-iso-PGF2 vs LDL cholesterol: 0.042
exact test for dichotomized variables according to mediafrom involvement of inflammatory and oxidative processes
on atherosclerosis. However, although inflammation works
hand in hand with oxidative modifications, oxidative stress
may also occur independent of inflammation. In support of
this, we found 8-iso-PGF2 and hs-CRP to be independent
predictors of PAD (Tables II and III). Thus, evaluation of
both 8-iso-PGF2 and hs-CRP should be superior to mea-
surement of either parameter alone.
Mass spectrometric methods and immunologic meth-
ods (radio immunoassay, enzyme immunoassay) have been
developed and validated for 8-iso-PGF2 determina-
tion.8,10 Enzyme immunoassays and gas chromatography–
mass spectrometry revealed rather incomparable results10;
the circulating 8-iso-PGF2 levels obtained in our study
therefore must be compared with the results of other
studies using the same assay (Cayman Chemicals).11,12
One of these studies12 focusing on circulating total 8-iso-
PGF2 and myocardial ischemia found 8-iso-PGF2 values
similar to our results. In another study11 investigating
oxidative stress in patients with CAD and control subjects
mean 8-iso-PGF2 plasma concentrations were higher than
in our report. However, in contrast to our work, both
studies included smokers, who exhibit higher 8-iso-PGF2
concentrations,18 and the latter study had a great propor-
tion of smokers, especially in the CAD group. In addition,
the prevalence of other confounding factors such as ad-
vanced age, sex, hypertension, obesity, and dyslipidemia in
the populations studied might have also influenced circu-
lating total 8-iso-PGF2 values to a different extent. Fur-
thermore, it must be mentioned that many of the control
subjects of our study, who had no PAD, no CAD, and no
CVD, per definition, exhibited carotid plaques as a sign of
mild but not clinically relevant atherosclerosis. Thus, it is
ntal lines, median) vs high-sensitivity C-reactive protein
cal lines, median) for entire study population (n 200).
th peripheral arterial disease; open circles, 100 control
e 4 squares. A, Spearman coefficient of rank correlation
rval, 0.216-0.060; P  .264). Fisher exact test for
hs-CRP levels, P .322. B, Spearman coefficient of rank
confidence interval, 0.097-0.180; P  .555). Fisher
so-PGF2 and LDL cholesterol levels, P  .888.orizo
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ts wi
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derestimated the real difference in circulating total 8-iso-
PGF2 levels in patients and control subjects.
In conclusion, serum total 8-iso-PGF2 was an inde-
pendent predictor of PAD in the present study. This find-
ing supports the hypothesis that 8-iso-PGF2 as an indica-
tor for oxidative stress is a risk marker for PAD, but awaits
confirmation in other studies.
We thank Sanofi-Synthelabo and Bristol-Myers Squibb
for providing 8-iso-PGF2 enzyme immunoassay kits; Maria
Kaar from our laboratory for performing the 8-iso-PGF2
enzyme immunoassay analyses; and Florian Kronenberg for
critical reading of the manuscript.
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